Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

Pascual-Salcedo, D., Plasencia, C., Ramiro, S., Nuno, L., Bonilla, G., Nagore, D., Ruiz del Agua, A., Martinez, A., Aarden, L., Martin-Mola, E., Balsa, A. · 2011 · Rheumatology

Abstract

OBJECTIVE: To analyse the clinical relevance of the production of anti-infliximab antibodies (anti-infliximab Abs) in patients with RA undergoing infliximab treatment over a prolonged period of time. METHODS: Clinical characteristics, serum trough infliximab and antibody levels were evaluated in 85 RA patients treated with infliximab for a median of 4.42 (interval 0.4-10.2) years. DAS in 28 joints (DAS-28), EULAR response criteria and survival of treatment were assessed at 3 time points (6 months, 12 months and >4 years). RESULTS: Antibodies against infliximab were detected in 28 (32.9%) patients and were present in all EULAR non-responder patients. Antibody levels were higher in EULAR non-responders throughout the study period (P = 0.05 at 6 months, P = 0.02 at 1 year, P = 0.003 at >4 years) compared with EULAR (good and moderate) responders. Nine (10.5%) patients, all of them with high-serum anti-infliximab Ab levels, developed infusion-related reactions. Patients with anti-infliximab Abs more often required increased infliximab doses (51.7%) (P = 0.032) and median survival time on treatment was shorter (4.15 vs 8.89 years) (P = 0.0006). MTX co-therapy was not associated with lower proportion of anti-infliximab Ab-positive patients, but those receiving both infliximab and MTX had lower levels of anti-infliximab Abs (P = 0.073) and longer survival (P = 0.015) on treatment. CONCLUSION: The formation of anti-infliximab Abs during treatment with infliximab is associated with a loss of clinical response, the appearance of infusion reactions and discontinuation of treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/rheumatology/ker124

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 256

Metadata

Authors
Pascual-Salcedo, D., Plasencia, C., Ramiro, S., Nuno, L., Bonilla, G., Nagore, D., Ruiz del Agua, A., Martinez, A., Aarden, L., Martin-Mola, E., & Balsa, A.
Venue
Rheumatology
Published
2011-03-22
Volume
50
Issue
8
Pages
1445-1452
ISSN
  • 1462-0324 (ISSN-L)
  • 1462-0332
OpenAlex
W2111046066
Cited by
256
References
22
FWCI
16.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. https://app.cochat.ai/papers/10.1093/rheumatology/ker124
The paper
Pascual-Salcedo, D., Plasencia, C., Ramiro, S., Nuno, L., Bonilla, G., Nagore, D., Ruiz del Agua, A., Martinez, A., Aarden, L., Martin-Mola, E., & Balsa, A. (2011). Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. https://doi.org/10.1093/rheumatology/ker124

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.